Aspirin in the primary prevention of cardiovascular disease in the Women's Health Study: Effect of noncompliance

European Journal of Epidemiology

Volumn 27, Issue 6, 2012, Pages 431-438

  Cook, Nancy R ^a,b   Cole, Stephen R ^c   Buring, Julie E ^a,b  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c The University of North Carolina at Chapel Hill   (United States)

Author keywords

Aspirin; Cardiovascular disease; Marginal structural model; Myocardial infarction; Stroke

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA TOCOPHEROL; PLACEBO;

ADULT; AGED; ANGINA PECTORIS; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CONTROLLED STUDY; DRUG EFFICACY; DRUG USE; FEMALE; HUMAN; INTENTION TO TREAT ANALYSIS; MAJOR CLINICAL STUDY; PATIENT COMPLIANCE; POSTMENOPAUSE; PRIMARY PREVENTION; REVASCULARIZATION; RISK FACTOR; TRANSIENT ISCHEMIC ATTACK; WOMEN'S HEALTH;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTICOAGULANTS; ASPIRIN; BODY MASS INDEX; CARDIOVASCULAR DISEASES; COMORBIDITY; CONTINENTAL POPULATION GROUPS; FEMALE; HEALTH BEHAVIOR; HUMANS; MEDICATION ADHERENCE; MIDDLE AGED; PRIMARY PREVENTION; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESEARCH DESIGN; RISK FACTORS;

EID: 84863704038     PISSN: 03932990     EISSN: 15737284     Source Type: Journal    
DOI: 10.1007/s10654-012-9702-x     Document Type: Article

References (21)

1. Antiplatelet Trialists' Collaboration. Secondary prevention of vascular disease by prolonged antiplatelet therapy. Brit Med J. 1988;296:320-31.
2. Hansson L, Zanchetti A, Carruthers SG, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: Principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet. 1998;351:1755-62.
3. The Medical Research Council's General Practice Research Framework. Thrombosis prevention trial: Randomised trial of low-intensity oral anticoagulation with warfarin and low-dose aspirin in the primary prevention of ischaemic heart disease in men at increased risk. Lancet. 1998;351:233-41.
4. The Steering Committee of the Physicians' Health Study Research Group. Final report on the aspirin component of the ongoing Physicians' Health Study. Steering Committee of the Physicians' Health Study Research Group [see comments]. N Engl J Med. 1989;321:129-35.
5. Peto R, Gray R, Collins R, et al. Randomised trial of prophylactic daily aspirin in British male doctors. Brit Med J. 1988;296:313-6.
6. Ridker PM, Cook NR, Lee IM, et al. A randomized trial of lowdose aspirin in the primary prevention of cardiovascular disease in women. N Engl J Med. 2005;352:1293-304.
7. Antithrombotic Trialists' (ATT) Collaboration. Aspirin in the primary and secondary prevention of vascular disease: Collaborative meta-analysis of individual participant data from randomized trials. Lancet. 2009;373:1849-60.
8. U.S. Preventive Services Task Force. Aspirin for the primary prevention of cardiovascular events: Recommendation and rationale. Ann Intern Med. 2002;136:157-60.
9. Robins JM, Hernan M, Brumback B. Marginal structural models and causal inference in epidemiology. Epidemiology. 2000;11: 550-60.
10. Cook NR, Cole SR, Hennekens CH. Use of a marginal structural model to determine the effect of aspirin on cardiovascular mortality in the Physicians' Health Study. Am J Epidemiol. 2002; 155:1045-53.
11. Rexrode KM, Lee IM, Cook NR, Hennekens CH, Buring JE. Baseline characteristics of participants in the Women's Health Study. J Womens Health Gend Based Med. 2000;9:19-27.
12. Cook NR, Lee IM, Gaziano JM, et al. Low-dose aspirin in the primary prevention of cancer. J Am Med Assoc. 2005;294:47-55.
13. Therneau TM, Grambsch PM. Modeling survival data: Extending the cox model. New York: Springer; 2000.
14. Robins JM. Association, causation, and marginal structural models. Synthese. 1999;121:151-79.
15. Hernán M, Brumback B, Robins JM. Marginal structural models to estimate the causal effect of zidovudine on the survival of HIV-positive men. Epidemiology. 2000;11:561-70.
16. D'Agostino RB, Lee ML, Belanger AJ, Cupples LA, Anderson K, Kannel WB. Relation of pooled logistic regression to time dependent Cox regression analysis: The Framingham Heart Study. Stat Med. 1990;9:1501-15.
17. Cole SR, Hernán MA. Constructing inverse probability weights for marginal structural models. Am J Epidemiol. 2008;168: 656-64.
18. Antithrombotic Trialists' Collaboration. Collaborative metaanalysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. Brit Med J. 2002;324:71-86.
19. U.S. Preventive Services Task Force. Aspirin for the prevention of cardiovascular disease: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2009;150:396-404.
20. Pradhan AD, Cook NR, Manson JE, Ridker PM, Buring JE. A randomized trial of low-dose aspirin in the prevention of clinical type 2 diabetes in women. Diab Care. 2009;32:3-8.
21. Bensenor IM, Cook NR, Lee IM, Chown MJ, Hennekens CH, Buring JE. Low-dose aspirin for migraine prophylaxis in women. Cephalalgia. 2001;21:175-83.